Myosin light chain kinase is necessary for smooth muscle contraction. Results: The kinase is limiting for aortic, but not bladder smooth muscle contraction. Conclusion: Myosin light chain kinase provides dissimilar contributions to signaling responses. Significance: Haploinsufficiency of myosin light chain kinase may affect aortic smooth muscle cell contractile tone in vivo. Ca
/calmodulin-dependent myosin light chain kinase (MLCK) phosphorylates smooth muscle myosin regulatory light chain (RLC) to initiate contraction. We used a tamoxifenactivated, smooth muscle-specific inactivation of MLCK expression in adult mice to determine if MLCK was differentially limiting in distinct smooth muscles. A 50% decrease in MLCK in urinary bladder smooth muscle had no effect on RLC phosphorylation or on contractile responses whereas an 80% decrease resulted in only a 20% decrease in RLC phosphorylation and contractile responses to the muscarinic agonist carbachol. Phosphorylation of the myosin light chain phosphatase regulatory subunit MYPT1 at Thr696 and Thr853 and the inhibitor protein CPI-17 were also stimulated with carbachol. These results are consistent with the previous findings that activation of a small fraction of MLCK by limiting amounts of free Ca All cells in the body contain myosin molecular motors that track on actin filaments to initiate motile events. The myosin II subfamily members, including smooth muscle myosin, are hexamers composed of heavy chain dimers and two pairs of myosin light chains (1, 2) . The heavy chain motor domain binds reversibly to actin filaments, hydrolyzes ATP and thereby converts chemical energy into mechanical force and movement. Smooth and nonmuscle myosins are activated by Ca 2+ /calmodulin-dependent MLCK 3 that phosphorylates the myosin regulatory light chain subunit RLC (3-5). Myosin light chain phosphatase dephosphorylates RLC to induce relaxation. RLC phosphorylation drives diverse cellular movements such as cell division, cell migration, and cell-matrix adhesion as well as smooth muscle contraction (1,2,6,7).
Neurotransmitters, hormones and cytokines act on cell surface receptors with assorted signal transduction pathways converging to increase [Ca 2+ ] i . Ca 2+ binds to calmodulin which then activates MLCK to phosphorylate RLC and initiate smooth muscle contraction (3-5). Signaling pathways also inhibit myosin light chain phosphatase, thereby increasing RLC phosphorylation without changing elevated [Ca 2+ ] i (Ca 2+ sensitization) (8-13). Many studies indicate that agonist-mediated Ca 2+ sensitization involving decreased myosin light chain phosphatase activity is due to two major signaling pathways, including phosphorylation of the regulatory subunit of the phosphatase, MYPT1, by a Rho kinase pathway (ROCK), and phosphorylation of a small inhibitor protein CPI-17 by PKC (14-17). Myosin light chain phosphatase activity may also be regulated by other kinases including ZIPK and ILK (13). The extent of RLC phosphorylation is thus balanced by the relative MLCK and myosin light chain phosphatase activities, each of which are regulated.
The quantitative and integrative relationships among the signaling molecules acting on RLC phosphorylation are not well understood, but obviously contribute to cell biological responses. In contrast to tonic vascular smooth muscle cells, phasic smooth cells in the intestine and urinary bladder have less CPI-17 protein and more myosin light chain phosphatase (18) (19) (20) 
EXPERIMENTAL PROCEDURES
Generation of Genetically Modified Mice-Mice containing floxed Mylk alleles (Mylk f/f )(4) were crossed with a SMMHC-CreER T2 transgenic mouse line expressing a fusion protein of the Cre recombinase with the modified estrogen receptor binding domain (CreERT2) under the control of the smooth muscle myosin heavy chain (SMMHC) promoter (29). Cre-mediated recombination occurred robustly and exclusively in smooth muscle cells in tissues, but only after tamoxifen treatment (29). Mice were bred and screened as previously described (4,29). Tamoxifen was injected intraperitoneally for five consecutive days at a dose of 1 mg/day. The tamoxifen (200 mg, Sigma) was dissolved in 2 ml of ethanol followed by 18 ml sunflower oil at a concentration 10 mg/ml and stored at -20°C for up to 1 month. Bladder and aortic tissues were harvested 18-20 days after starting tamoxifen treatment from transgenic mice containing Mylk 
Preparation of Smooth Muscle Strips from Mice-
The isolated urinary bladder was opened, and the urothelium and adventia were removed by blunt dissection to enrich for smooth muscle cells. The smooth muscle layer was dissected into longitudinal strips (0.5 × 0.5 × 8.0 mm) that were mounted on an isometric force apparatus in PSS (in mM: 118.5 NaCl, 4.75 KCl, 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 24.9 NaHCO 3 , 1.6 CaCl 2 , 10.0 Dglucose, pre-gassed with 95% O 2 /5% CO 2 at 35° C). Strips were equilibrated and stretched 1.2 times slack length. After mounting, strips were equilibrated for 30 min, and pre-contracted with 65 mM KCl three times. At the end of the equilibration, 65 mM KCl (pretreated with 0.1 µM atropine for 10 min) or the muscarinic agonist, 10 µM carbachol (Sigma) were added to initiate contractile responses. For Ca 2+ depletion, the strips were treated with 10 µM carbachol for a period of 30 sec, and then washed with PSS containing no added Ca 2+ plus 1 mM EGTA. This protocol was repeated at 2 min intervals for 5 to 6 times. The strips were then treated with 10 µM carbachol for 30 sec and 1 µM calyculin A (Enzolite Sciences) for 30 min or 10 µM carbachol for 30 sec in the presence or absence of Ca 2+ . Force measurements were recorded isometrically by a Grass FT03 force transducer connected to Powerlab 8/SP data acquisition unit (AD instruments, Colorado Springs, CO). Stresses (dynes/cm 2 ) were calculated to normalize contraction responses to tissue cross-sectional areas. Contractile studies were also performed by similar procedures for ileal smooth muscle.
The aorta was isolated and endothelial cells removed by gentle swabbing and excessive adventia removed by dissection. Thoracic aortic segmental rings 5 mm long were mounted by triangular wires to the isometric force apparatus. Aortic rings were passively stretched to 1.8-2.0 g and remained quiescent for 60 min before precontraction by 65 mM KCl in Krebs-Ringer solution. Aortic rings were also treated with 10 µM phenylephrine and force responses obtained as described above. Force measurements were normalized as grams of developed force per tissue wet weight. Contractile studies were also performed by similar procedures for tracheal rings.
At indicated times after specific treatments tissues were quick frozen by clamps prechilled in liquid nitrogen for protein phosphorylation measurements. Frozen muscles were processed as previously described (23) by immersion in a frozen slurry of 10% trichloroacetic acid in acetone containing 10 mM dithiothreitol for 30 minutes, then thawed and transferred to Eppendorf tubes. Tissues were rinsed with ether (3 times for 5min), briefly dried (3 min), and suspended in urea sample buffer containing 18.5 mM Tris (pH 8.6), 20.4 mM glycine, 10 mM dithiothreitol, 4 mM EDTA, and 5% sucrose. Proteins were then solubilized in a Bullet Blender (Next Advance, Inc, Averill Park, NY) (with 2 mm zirconium oxide beads, 4 spins x 3 min each at setting 9). Protein content was determined by Bradford assay and bromophenol blue was added to 0.004%. Samples were stored at -80°C. Western Blot Analysis following SDS-PAGEProtein samples solubilized in urea sample buffer were added to 0.2 volumes of SDS sample buffer containing 250 mM Tris (pH 6.8), 10% SDS, 50 mM dithiothreitol, 40% glycerol, and 0.01% bromophenol blue, boiled, and loaded by amount of protein for SDS-PAGE (10-20% acrylamide gradient). Proteins were transferred to a nitrocellulose membrane and visualized by immunoblot staining using antibodies to MLCK (K36, Sigma), ILK (Sigma), ROCK1 (Santa Cruz), CPI-17 total (17), MYPT1 total (Upstate), phospho-MYPT1 (Thr853) (Upstate), phospho-MYPT1 (Thr696) (Upstate), phospho-CPI-17 (Santa Cruz) and SMMHC (30). The mouse monoclonal antibody from Sigma (K36) raised to the short MLCK binds the kinase near the Nterminus. Long MLCK is identical to short MLCK except for the extension at the N-terminus so this antibody binds to both forms of the enzyme (31). Because tissues from bladder and aortic smooth muscles were carefully dissected to remove urothelium (bladder) or endothelial cells (aorta) as well as adventia, the tissue strips were highly enriched for smooth muscle cells. We observed no long MLCK in our western blots (data not shown). GAPDH was stained with anti-GAPDH antibody (Santa Cruz) or actin was stained with Coomassie Brilliant Blue G-250 as a loading control. MLCK, ILK, ROCK1, MYPT1 total and CPI-17 total amounts were expressed as ratio of relative protein to GAPDH loading control. Additionally, MLCK content was also normalized to the total amount of SMMHC determined by western blotting with antibodies previously characterized (30). There were no significant differences between normalization with GAPDH or smooth muscle myosin heavy chain, indicating enrichment of smooth muscle cells in the dissected tissues. 
RESULTS

MLCK content varies in different smooth muscle tissues-Quantitation of immunoblots for
MLCK in different smooth muscle tissues from wildtype mice showed significant variation in content with the greatest amount in bladder smooth muscle relative to other smooth muscles ( Fig. 1 ). Aortic tissue contained less than 50% MLCK compared to bladder.
We observed no diminishments of MLCK protein in aortas from Mylk f/f mice containing the SMMHC-CreERT2 transgene without tamoxifen treatment compared to aortas from wild type mice.
Additionally, tamoxifen treatment of Mylk +/f mice containing the SMMHC-CreERT2 transgene predictably reduced bladder and aortic MLCK by 50% (MLCK SM+/-mice), consistent with inactivation of the one floxed allele with induced recombination (Fig. 1) . Inactivation of both alleles decreased MLCK expression further in both tissues with the amount in bladder reduced 80% while aortic tissues were reduced >90%. Tissues were harvested from these animals before MLCK protein was fully extinguished because of impending death related to the essential role of MLCK in smooth muscle maintenance of homeostasis (4). Because the amount of MLCK in bladder smooth muscle was so much more than that found in aortic smooth muscle, the residual amount of kinase was greater.
The amounts of other proteins relevant to signaling to RLC phosphorylation (MYPT1, CPI-17, ROCK1 and ILK) were not changed in bladder or aortic tissues from MLCK SM-/-mice (data not shown). The amounts of actin and myosin were also not reduced (data not shown). Thus, the conditional inactivation of MLCK alleles in adult mice reduces MLCK protein expression, but not that of related contractile proteins.
Distinct effects on developed contractile force, RLC phosphorylation and Ca
2+ sensitization are related to reductions in MLCK content-When both MLCK alleles were inactivated in MLCK SM-/-mice after tamoxifen treatment, the 80% reduction in MLCK content in bladder smooth muscle tissue produced less reductions in the responses to KCl and the muscarinic agonist carbachol. As shown in Figs. 2 and 3, maximal force development and RLC phosphorylation induced by KCl treatment were reduced 50% while the lower phasic responses at 5 min were similar to those measured in tissues from MLCK SM+/+ mice. However, the maximal responses to carbachol were reduced less than those observed with KCl. Thus, the potential GPCR recruitment of Ca 2+ sensitization via inhibition of myosin light chain phosphatase may blunt the effects of the decrease in MLCK in bladder smooth muscle from MLCK SM-/-mice.
Aortic tissue responses were also affected in MLCK SM-/-animals. The initial force development and extent of RLC phosphorylation in response to treatment with KCl or the α-adrenergic agonist phenylephrine were both greatly attenuated (Figs.
2 and 3). Additionally, sustained tonic responses were also inhibited markedly. Thus, the greater reduction in MLCK content in tonic aortic smooth muscle cells from MLCK SM-/-mice had a more profound effect on developed contractile force and RLC phosphorylation responses. Ca 2+ sensitization responses with MYPT1 and CPI-17 phosphorylation were measured in tissues from MLCK SM-/-mice. With the gradient gel system used for these analyses, the different isoforms for MYPT1 and CPI-17 were resolved (33,34). KCl treatment of bladder smooth muscles from MLCK SM+/+ mice showed modest increases in MYPT1 and CPI-17 phosphorylation (Fig. 4) . However, KCl-induced phosphorylation of MYPT1 as well as CPI-17 was enhanced in bladder tissues from MLCK SM-/-mice ( mice showed modest phosphorylation responses with phenylephrine treatment. However, the maximal responses obtained were enhanced in MLCK SM-/-mice at 15 sec but not 5 min. In spite of these enhanced phosphorylation responses, contractile force development and RLC phosphorylation remained greatly impaired ( Fig. 2  and 3 ). Aortic smooth muscle cells do not have robust Ca 2+ sensitization responses.
We determined the effects of inactivation of a single Mylk allele in MLCK SM+/-mice. In bladder tissues, the 50% reduction of MLCK (Fig. 1 ) resulted in no significant changes in the contractile responses to KCl or carbachol (Fig. 7) . However, the responses in the aorta were affected with a 44% reduction in initial force development at 15 sec with KCl treatment and a smaller reduction in response to phenylephrine treatment (Fig. 7) . As predicted from the contractile results, there were no differences in RLC phosphorylation responses in bladder tissues whereas RLC phosphorylation was reduced in aortic tissues from MLCK SM+/-mice (Fig. 7) -dependent unless myosin light chain phosphatase is chemically inhibited-Bladder smooth muscle tissues incubated in Ca 2+ -free PSS were not able to contract and lost the RLC phosphorylation response when exposed to carbachol (Fig. 8) . Similar responses were obtained with tissues from MLCK SM+/+ and MLCK SM-/-mice. Thus, Ca 2+ -independent kinases such as ROCK, ILK or ZIPK do not appear to contribute to RLC and contractile force development responses in bladder tissues from these mice. However, if the tissues were incubated with the myosin light chain phosphatase inhibiter calyculin A in the absence of Ca 2+ , RLC phosphorylation slowly increased leading to force development with a significant change in the RLC phosphorylation pattern. Treatment of tissues with KCl or carbachol in the presence of Ca 2+ resulted in monophosphorylated RLC (Fig. 5) . Calyculin A treatment, however, produced diphosphorylated RLC, consistent with phosphorylation by ILK or ZIPK (Fig. 8) (35,36) .
Similar results on Ca 2+ -dependence of RLC phosphorylation and force development were obtained with aortic tissues (Fig. 9) (43) . Stimuli that lead to physiological contractions result predominately in RLC monophosphorylation and the knockout of MLCK in adult smooth muscle tissues eliminates RLC phosphorylation as shown in this study and previous publications (4,5,10,40,44). However, pathological situations may lead to significant RLC diphosphorylation by ILK and ZIP kinase in smooth muscle tissues (45) . Thus, the Ca 2+ /calmodulin-dependent MLCK appears to be the only kinase that phosphorylates RLC physiologically in adult smooth muscle tissues.
Interestingly, isolated blood vessels from embryonic MLCK-null mice contract, presumably due to RLC phosphorylation (46) . These results are consistent with another observation that embryonic fibroblasts contain no MLCK and RLC is phosphorylated by ROCK (47) . Thus, MLCK is not the only kinase that can phosphorylate RLC in embryonic cells. Additionally, ROCK may serve as the primary kinase for phosphorylation of nonmuscle myosin in other kinds of cells (48) (49) (50) .
The amount of cellular MLCK is an important consideration regarding signaling to RLC phosphorylation in muscle cells. There are significant differences in MLCK activities in smooth, skeletal and cardiac muscle consistent with physiological functions (3,51,52). The greater amount of MLCK activity is found in smooth muscle tissues and supports the rapid rate of RLC phosphorylation necessary to initiate contraction. In fast-twitch skeletal muscle fibers, the rates of phosphorylation-dephosphorylation are slower where sustained RLC phosphorylation enhances contractile force with repeated contractions that occur during exercise (postactivation potentiation). RLC phosphorylation-dephosphorylation is much slower in cardiac muscle where MLCK maintains the extent of RLC phosphorylation at 45% in the constantly beating heart. This phosphorylation is physiologically important for enhancing myofilament contractile force (52) .
Differences in MLCK content may vary in different smooth muscles. Measurements of MLCK activity in tissue homogenates showed a three-fold difference between the phasic ileum and tonic femoral artery smooth muscle tissues (19). Using a highly specific monoclonal antibody for MLCK for western blotting, we find more modest differences among different phasic and tonic smooth muscles. Although heavy meromyosin was used as a selective substrate in the previous study (19), the possibility remains that another kinase(s) contributed to its phosphorylation. The greatest difference we observed was the two fold greater amount of MLCK content in bladder smooth muscle compared with aortic smooth muscle.
We had previously determined that free Ca 2+ /calmodulin was limiting for MLCK activation in bladder smooth muscle, and thus, only a fraction of the kinase was activated in responses to carbachol or KCl (17, 23 Mizuno, Y., Isotani, E., Huang, J., Ding, H., Stull, J. T., and Kamm, K. E. Isotani, E., Zhi, G., Lau, K. S., Huang, J., Mizuno, Y., Persechin, A., Geguchadze, R., Kamm, K. E., and J.T., S. Wirth, A., Benyo, Z., Lukasova, M., Leutgeb, B., Wettschureck, N., Gorbey, S., Orsy, P., Horvath, B., Maser-Gluth, C., Greiner, E., Lemmer, B., Schutz, G., Gutkind, S., and Offermanns, S. by guest on November 15, 2017
